AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05030792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention-restorative therapy (ART)-based virtual reality (VR)
Description: The ART-based VR intervention will be provided using an Oculus Go™ which is a commercially available, all-in-one VR headset with a handheld controller.
Study NCT06202742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy for insomnia
Description: Online meeting, weekly for 8 weeks, to deliver CBTI by psychologist/ psychiatrist
Study NCT06202742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Online meeting, weekly for 8 weeks, to deliver general health knowledge
Study NCT05658900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enucleation with albumin PRF
Description: The protocol that will be used in the preparation of albumin PRF~1. A sample of venous blood, at ten milliliters, at least will be drawn from the patient in a sterile centrifuge tube.~2. The venous blood sample will be centrifuged at 700 g for 8 minutes.~   \* Betadine: Povidone-iodine, 7.5% (0.75% available iodine), Purdue Products L.P~3. The platelet-poor plasma layer will be taken and heated at uniform temperature 75 celsius for 10 minutes in a thermostatic water bath incubator to denature albumin protein forming albumin gel.~4. Once the albumin gel is cooled, to room temperature for 10 minutes, it will be mixed with the buffy coat layer of PRF using 3 way stop cock and 2 plastic syringes with Luer lock to obtain albumin PRF then leave it in the dappen dish for 5 minutes.
Study NCT05658900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enucleation without albumin PRF
Description: The full-thickness mucoperiosteal flap will be performed using blade no. 15 and Bard- Parker handles extending one tooth anterior and one tooth posterior to the cystic cavity.~The mucoperiosteal flap will be reflected using the periosteal elevator to expose the bone.~Removal of the overlying bone to expose the cystic lesion. Enucleation of the cyst.
Study NCT06404736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bispecific antibody (bsAb) targeting PD-1 and CLTA-4
Description: QL1706 is a novel bispecific combination antibody composed of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 (programmed cell death protein 1) (PSB103) and a recombinant humanized IgG1 monoclonal antibody targeting human CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (PSB105). Both antibodies have undergone engineering modifications to introduce mutations facilitating their correct assembly and preventing mispairing, and are expressed in the same cell line at a predetermined ratio (approximately 2:1).
Study NCT06404736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Albumin-bound paclitaxel improves the solubility and delivery of paclitaxel to tumor cells by binding to human albumin, facilitating its transportation through the bloodstream and enhancing its uptake into tumor tissue. It works by binding to and stabilizing microtubules within cancer cells, thereby disrupting the normal process of cell division and leading to cell cycle arrest and apoptosis, ultimately resulting in the death of cancer cells.
Study NCT06404736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is a chemotherapy medication belonging to the platinum-based class of drugs, commonly used in the treatment of various cancers, including ovarian cancer, lung cancer, and bladder cancer. It functions by forming DNA adducts, disrupting DNA replication and transcription processes in cancer cells, ultimately leading to cell death. Despite its efficacy, carboplatin can cause side effects such as nausea, vomiting, and bone marrow suppression.
Study NCT06498323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenecteplase
Description: Intravenous thrombolytic agents administration
Study NCT06498323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenecteplase
Description: Intravenous thrombolytic agents administration
Study NCT05407168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care
Study NCT05407168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: View decision aid
Study NCT05407168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05407168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06157008 — intervention group
Intervention type: DRUG
Intervention: General Anesthetics
Description: General anesthetics used in spinal cord electrical stimulator insertion surgery
Study NCT05342766 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Nutrigenetic
Description: Each grup will receive two interventions (Nutrigenetic and Standard), in a cross-over design (3 months each), spaced by a wash-out period (3 months).
Study NCT05747183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ProTaper Ultimate
Description: Root canal preparation using ProTaper Ultimate files.
Study NCT05747183 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ProTaper Gold
Description: Root canal preparation using ProTaper Gold files.
Study NCT04951583 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FMT + ICI
Description: This study will include 3 cohorts of patients: (1) Patients with advanced or unresectable NSCLC, (2) patients with advanced or unresectable melanoma, and (3) patients with unresectable or advanced uveal melanoma. Patients with NSCLC, melanoma, uveal melanoma and will be analyzed in three separate subgroups given their differing clinical outcomes.~Each group will be treated with ICI as per their respective first line options, in combination with investigational FMT capsules.
Study NCT06583265 — intervention group
Intervention type: DRUG
Intervention: Observational
Description: To observe if endometrial compaction ≥ 5% in down regulated FET cycles increases clinical pregnancy rate.
Study NCT06584201 — intervention group
Intervention type: PROCEDURE
Intervention: Erector Spinae Plane Block (ESP)
Description: The ESP block will be administered before the VATS procedure, aiming to manage postoperative pain and minimize the impact on early lung function test (SFT) parameters. The block will be performed using standard techniques under ultrasound guidance to ensure accurate placement.
Study NCT06584201 — intervention group
Intervention type: PROCEDURE
Intervention: Paravertebral Block (PVB)
Description: The PVB will be administered prior to the VATS procedure, with the objective of managing postoperative pain and assessing its impact on early postoperative lung function (SFT) parameters. This block will also be performed using standard techniques and ultrasound guidance for precision.
Study NCT05122091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib + SOX
Description: Fruquintinib：5mg qd for 2 weeks on and 1 week off, q3w； SOX: Tegafur gimeracil oteracil potassium capsule: 40-60mg bid（dosage according to body surface area），d1-14，q3w； Oxaliplatin：130mg/m2，intravenous (IV) ，d1，q3w.
Study NCT06392243 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intracardiac ultrasound imaging system
Description: The control group was treated with SOUNDSTAR 3D Diagnostic Ultrasound catheter (SNDSTR10G) and Vivid IQ, intracardiac and macrovascular imaging of the heart, assessment of intracardiac Doppler flow, and guidance for intracardiac intervention
Study NCT06392243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracardiac ultrasound imaging system
Description: The control group was treated with SOUNDSTAR 3D Diagnostic Ultrasound catheter (SNDSTR10G) and Vivid IQ, intracardiac and macrovascular imaging of the heart, assessment of intracardiac Doppler flow, and guidance for intracardiac intervention
Study NCT04040829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (CR)
Description: Cognitive remediation therapy is a behavioral intervention that aims to improve cognition. This intervention has the goal to produce long-term improvements in cognition as well as to generalize these improvements in daily functioning.
Study NCT04040829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported education (SE)
Description: Supported education (SE) is a behavioral intervention that aims to help people return to school and/or succeed in school. SE offers a wide range of services that are personalized to the needs of each patients.
Study NCT04040829 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supported education (SE)
Description: Supported education (SE) is a behavioral intervention that aims to help people return to school and/or succeed in school. SE offers a wide range of services that are personalized to the needs of each patients.
Study NCT04040829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: Treatment as usual (TAU) consists of medication and routine contact with the clinical team.
Study NCT04040829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Treatment as usual (TAU) consists of medication and routine contact with the clinical team.
Study NCT04279522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relivion®DP- Active
Description: Relivion®DP- Active stimulation device
Study NCT04279522 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Relivion®DP- Sham
Description: Relivion®DP- Sham stimulation device
Study NCT05412368 — intervention group
Intervention type: OTHER
Intervention: Focus Groups
Description: Focus Groups
Study NCT04702022 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 18FDG PET / CT
Description: The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events will be applied.
Study NCT04903054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lulizumab
Description: Lulizumab is a pegylated, humanized monovalent domain antibody construct that is specific for human cluster of differentiation CD28.
Study NCT04903054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Standard of Care: Renal transplant rejection prophylaxis.
Study NCT04903054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin®
Description: Standard of Care: Renal transplant rejection prophylaxis.
Study NCT04903054 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin®
Description: Standard of Care: Renal transplant rejection prophylaxis.
Study NCT04903054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Standard of Care: Renal transplant rejection prophylaxis.
Study NCT04903054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Standard of Care: Renal transplant rejection prophylaxis.
Study NCT06377670 — intervention group
Intervention type: PROCEDURE
Intervention: Wassel IV Thumb Duplication Surgery
Description: This intervention involves the surgical correction of Wassel IV thumb duplication, which is a congenital hand anomaly. The study retrospectively evaluates the outcomes of various surgical techniques that have been employed to correct this condition, with a focus on functionality and aesthetics of the thumb post-surgery. Data collected post-intervention include preoperative metacarpophalangeal angle, type of skin flap, surgical reconstruction technique, immobilization method, and postoperative complications. Additionally, patient satisfaction and daily pain levels are assessed using standardized questionnaires. Each patient serves as their own control, with outcomes compared to their contralateral healthy thumb.
Study NCT04903054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Standard of Care: Renal transplant rejection prophylaxis.
Study NCT04903054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Standard of Care: Renal transplant rejection prophylaxis.
Study NCT04903054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Standard of Care: Renal transplant rejection prophylaxis.
Study NCT04903054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Standard of Care: Renal transplant rejection prophylaxis.
Study NCT06458985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosing Recovery: A Decision Aid and Toolkit
Description: The Disclosing Recovery intervention is designed to help people in treatment for opioid use disorder (1) make key decisions regarding disclosure, including whether, why, what, how, and when to disclose, and (2) build skills to disclose, including planning what to say, practicing disclosure, and preparing for negative responses.
Study NCT04548791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor VIIa variant
Description: Single intravenous dose and ascending doses of subcutaneous injection of MarzAA, followed by a fixed dose of MarzAA for the treatment of bleeding episodes
Study NCT05145829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Test: Sentinel node mapping using MRI
Description: Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
Study NCT05677542 — intervention group
Intervention type: DRUG
Intervention: secukinumab
Description: all patients who received secukinumab
Study NCT06224491 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Reflex locomotion according to Vojta
Description: Tactile stimulation according to Vojta´s reflex locomotion
Study NCT06224491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflex locomotion according to Vojta
Description: Tactile stimulation according to Vojta´s reflex locomotion
Study NCT05033821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted FOY+ImPACT
Description: The Adapted FOY+IMPACT is a selective, group-level intervention designed to prevent sexual risk-taking and substance use among adolescents affected by parental drug use. There are eight sessions for youth (FOY) and one session with youth and adults (ImPACT).
Study NCT05299905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual reality using Semi-CAVE
Description: The Semi-CAVE will use two screens positioned at a corner of the room, each with a ceiling-mounted short throw projector in front. The participant will stand in the middle of the area, giving them a viewing angle of roughly 180 degrees. The participant will be wearing a safety harness secured to an overhead guide rail, if necessary. The participant may be standing freely, on a treadmill, or on a step stool depending on the type of activity to be performed. The participant will interact with the system through motion sensors positioned at the corners of the area. To one side of the area will be a sufficiently powerful computer running the software. The projectors will be connected to this computer via HDMI cables or similar.
Study NCT05299905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual reality using the HMD
Description: The HMD will be a commercially available device that uses handheld controllers to control movement while in the VE. The researchers will use a room-scale set-up where a 3 m x 3 m square space is required. Oculus Quest 2 Controllers will be used to interact with the VE. The user will be positioned at the center of the square by default. A therapist will assist them through a separate program called the Observation Module. This program will let the therapist view what the patient can see in the HMD. This will also be used by the therapist to guide the patient navigate through the VE and give instructions for the activities.
Study NCT06037486 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glucometer Test
Description: measurement of the blood glucose concentration using the blood glucose monitor for personal use
Study NCT04708366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006
Description: Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
Study NCT04708366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MoviPrep
Description: Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
Study NCT04708366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrogol 400
Description: Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
Study NCT04863872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proactive Care Management
Description: Participants will receive one telephone nurse outreach call with follow up by the nurse or their primary care provider as clinically indicated.
Study NCT04863872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive Care Management
Description: Participants will receive one telephone nurse outreach call with follow up by the nurse or their primary care provider as clinically indicated.
Study NCT04863872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: my hypo compass education program
Description: Participants will be enrolled in a structured education program designed to improve hypoglycemia awareness and reduce severe hypoglycemia. The structured program will include 2 online group education sessions, 2 nurse follow up calls and use of glucose and hypoglycemia diaries, delivered over approximately 3 months.
Study NCT06365164 — intervention group
Intervention type: BEHAVIORAL
Intervention: Tactile stimulation
Description: The procedure consists of brief perioral tactile stimulation. The procedure is filmed in order to record and evaluate the response of the newborn to the stimulation. During the same intervention, each newborn will receive external stimulation (the experimenter repeatedly and regularly touches the corner of the infant's mouth slowly with the tip of his index finger) followed by facilitated self-stimulation (the experimenter will place the newborn's elbow close to his body, allowing him to touch his face alone with his hand). There will also be an initial phase and a final 30-second phase in which the newborn is observed without any stimulation.
Study NCT05118698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gynostemma
Description: Patients in the high-dose group and low-dose group will take gynostemma powder with a saponin content of 12% and 8% respectively, 3 times a day for 3 months.
Study NCT05118698 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Spinach
Description: For the spinach powder group, each patient will take spinach powder with nearly no saponin content, 3 times a day for 3 months.
Study NCT06109207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab will be given at at a dose of 200 mg intravenously every three weeks on day 1 of a planned 21-day cycle, and two doses before surgery
Study NCT06109207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib 100mg
Description: Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
Study NCT06109207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib 150mg
Description: Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
Study NCT06112366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery of impacted mandibular wisdom teeth
Description: All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with saline and the wound edges were sealed with tissue adhesive containing cyanoacrylate.